Under construction – not a live service
Sign in
Taking people in GermanyPhase 1/2

Tests PXS-5505 with azacitidine in people with myelodysplastic syndrome or CMML

Tests PXS-5505 with azacitidine in adults with myelodysplastic syndrome or CMML.

Key facts

Who runs it
Heidelberg University
Where
Bonn, Dresden, Duesseldorf, Goettingen, Hanover, Luebeck, Mainz, Mannheim, Munich, and Oldenburg, GermanySee the 10 sites
Trial code
Registry title
AZALOX Study: Safety and Efficacy of PXS-5505 with 5-Azacitidine in MDS and CMML Patients
Status
Recruiting
Phase
Phase 1/2
People taking part
42 people, planned
Started
3 Jul 2025
Expected to end
30 Jun 2028
Type of study
Interventional
Record updated
16 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with myelodysplastic neoplasms (MDS) or chronic myelomonocytic leukemia (CMML). It tests PXS-5505 together with 5-azacitidine.

Age
18 years or older
Sex
All sexes can join.

Where in Germany

  • Universitaetsklinikum Bonn AöRBonn, GermanyTaking people
  • Universitaetsklinikum Carl Gustav Carus Dresden an der Technischen Universitaet Dresden AöRDresden, GermanyTaking people
  • Universitaetsklinikum Duesseldorf AöRDuesseldorf, GermanyTaking people
  • Universitaetsmedizin GoettingenGoettingen, GermanyTaking people
  • Medizinische Hochschule HannoverHanover, GermanyTaking people
  • Universitaetsklinikum Schleswig-Holstein AöRLuebeck, GermanyTaking people
  • Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöRMainz, GermanyTaking people
  • Heidelberg UniversityMannheim, GermanyTaking people
  • Klinikum der Technischen Universitaet Muenchen (TUM Klinikum)Munich, GermanyTaking people
  • Klinikum Oldenburg AorOldenburg, GermanyTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Plain-language title
Tests PXS-5505 with azacitidine in people with myelodysplastic syndrome or CMMLGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
16 October 2026